Legend Biotech Corporation (LEGN)
LEGN Stock Price Chart
Explore Legend Biotech Corporation interactive price chart. Choose custom timeframes to analyze LEGN price movements and trends.
LEGN Company Profile
Discover essential business fundamentals and corporate details for Legend Biotech Corporation (LEGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Jun 2020
Employees
2.60K
Website
https://www.legendbiotech.comCEO
Ying Huang
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
LEGN Financial Timeline
Browse a chronological timeline of Legend Biotech Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.10, while revenue estimate is $280.66M.
Earnings released on 11 Aug 2025
EPS came in at -$0.34 falling short of the estimated -$0.22 by -54.55%, while revenue for the quarter reached $255.95M , missing expectations by -7.99%.
Earnings released on 13 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.40 by +82.50%, while revenue for the quarter reached $195.05M , missing expectations by -10.54%.
Earnings released on 11 Mar 2025
EPS came in at -$0.15 surpassing the estimated -$0.39 by +61.54%, while revenue for the quarter reached $186.52M , missing expectations by -2.50%.
Earnings released on 9 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.54 by +90.74%, while revenue for the quarter reached $186.52M , beating expectations by +38.48%.
Earnings released on 13 May 2024
EPS came in at -$0.16 surpassing the estimated -$0.29 by +44.83%, while revenue for the quarter reached $93.99M , missing expectations by -25.75%.
Earnings released on 11 Mar 2024
EPS came in at -$0.40 surpassing the estimated -$0.70 by +42.86%, while revenue for the quarter reached $79.46M , missing expectations by -8.16%.
Earnings released on 20 Nov 2023
EPS came in at -$0.17 surpassing the estimated -$0.56 by +69.64%, while revenue for the quarter reached $96.01M , missing expectations by -1.28%.
Earnings released on 15 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.69 by +60.87%, while revenue for the quarter reached $73.33M , beating expectations by +34.25%.
Earnings released on 18 May 2023
EPS came in at -$0.40 surpassing the estimated -$0.56 by +28.57%, while revenue for the quarter reached $36.34M , missing expectations by -33.55%.
Earnings released on 30 Mar 2023
EPS came in at -$0.85 falling short of the estimated -$0.44 by -94.17%, while revenue for the quarter reached $27.63M , missing expectations by -23.37%.
Earnings released on 30 Sept 2022
EPS came in at -$0.54 , while revenue for the quarter reached $27.36M .
Earnings released on 1 Jun 2022
EPS came in at -$0.24 surpassing the estimated -$0.37 by +35.14%, while revenue for the quarter reached $11.97M , missing expectations by -52.12%.
Earnings released on 18 Mar 2022
EPS came in at -$0.38 falling short of the estimated -$0.35 by -8.57%, while revenue for the quarter reached $40.83M , beating expectations by +186.09%.
Earnings released on 31 Dec 2021
EPS came in at -$0.60 , while revenue for the quarter reached $39.00M .
Earnings released on 16 Nov 2021
EPS came in at -$0.43 falling short of the estimated -$0.35 by -22.86%, while revenue for the quarter reached $16.88M , beating expectations by +115.51%.
Earnings released on 23 Aug 2021
EPS came in at -$0.32 falling short of the estimated -$0.31 by -3.23%, while revenue for the quarter reached $20.23M , beating expectations by +158.40%.
Earnings released on 18 May 2021
EPS came in at -$0.30 surpassing the estimated -$0.35 by +14.29%, while revenue for the quarter reached $13.68M , missing expectations by -12.50%.
Earnings released on 18 Mar 2021
EPS came in at -$0.22 surpassing the estimated -$0.28 by +21.43%, while revenue for the quarter reached $40.78M .
Earnings released on 16 Nov 2020
EPS came in at -$0.50 falling short of the estimated -$0.31 by -61.29%, while revenue for the quarter reached $11.75M , beating expectations by +4.38%.
LEGN Stock Performance
Access detailed LEGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.